证券代码：300289 证券简称：利德曼 公告编号：2023-059 北京利德曼生化股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2023 年 3 月 15 日召开第五届董事会第九次会议和第五届监事会第七次会议，审议通过 了《关于继续使用部分闲置募集资金进行现金管理的议案》，同意公司在 不影响募集资金使用计划和确保募集资金安全的情况下，继续使用额度 不超过人民币 28,000 万元的闲置募集资金进行现金管理，投资安全性高、 流动性好、低风险、稳健性的保本型产品，使用期限自公司董事会审议 通过之日起 12 个月，在前述额度及期限范围内，资金可循环滚动使用， 并授权公司董事长行使相关投资决策权，财务负责人办理具体相关事宜。 具体内容详见公司于2023年 3月 15日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于继续使用部分闲置募集资金进行现金管理的公告》（公告编 号：2023-011）、以及后续披露的《关于使用闲置募集资金进行现金管理 的 ...

Financial Performance - The company's revenue for Q3 2023 was ¥113,185,912.28, a decrease of 32.50% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2023 was ¥7,278,611.85, down 30.90% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥8,132,619.20, a decline of 6.34% compared to the previous year[4] - Total operating revenue for Q3 2023 was CNY 340,139,251.33, a decrease of 37.2% compared to CNY 541,955,931.31 in the same period last year[24] - Net profit for Q3 2023 was CNY 28,660,100.41, representing a decline of 42.5% from CNY 49,863,077.17 in Q3 2022[25] - Earnings per share for Q3 2023 were CNY 0.0437, down from CNY 0.0634 in the previous year, reflecting a decrease of 30.5%[26] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,946,564,124.31, a decrease of 2.53% from the end of the previous year[4] - Total current assets amount to ¥1,103,432,160.39, a slight decrease from ¥1,110,505,444.50 at the beginning of the year[21] - Total assets as of September 30, 2023, are ¥1,946,564,124.31, compared to ¥1,997,134,641.92 at the beginning of the year[21] - Total liabilities decreased to CNY 137,436,620.78 from CNY 216,667,238.80, a reduction of 36.5%[25] - Total equity increased to CNY 1,809,127,503.53 from CNY 1,780,467,403.12, an increase of 1.6%[25] Cash Flow - Operating cash flow for the year-to-date was ¥115,343,682.07, an increase of 47.32% compared to the same period last year[4] - In Q3 2023, the net cash flow from operating activities was ¥115,343,682.07, an increase from ¥78,295,528.10 in Q3 2022, representing a growth of approximately 47.3%[28] - The total cash outflow from operating activities amounted to ¥331,265,077.19, down from ¥589,458,333.85 in the same period last year, indicating a decrease of about 43.8%[28] - The net cash flow from investing activities was -¥286,472,902.94, slightly improved from -¥327,437,026.83 in Q3 2022[28] - The total cash inflow from investing activities was ¥261,899,636.17, compared to ¥332,995,966.03 in Q3 2022, reflecting a decline of about 21.4%[28] - The cash outflow for investment activities was ¥548,372,539.11, down from ¥660,432,992.86 in the previous year, a decrease of approximately 17%[28] - The net cash flow from financing activities was -¥10,410,469.32, an improvement from -¥22,371,478.25 in Q3 2022[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21,946[15] - The largest shareholder, Guangzhou High-tech Zone Technology Holding Group Co., Ltd., holds 46.35% of shares, totaling 252,133,152 shares[15] - The company has 126,213,152 restricted shares, which will not be transferable for 36 months from the date of issuance[18] - The company plans to unlock 25% of the executive locked shares annually, with 855,000 shares added this period[18] Operating Costs and Income - The company's operating income for the first nine months of 2023 was ¥340,139,251.33, a decrease of 37.24% year-on-year, primarily due to policy adjustments[10] - The company's operating costs for the first nine months of 2023 were ¥148,280,677.29, down 51.44% year-on-year[10] - Total operating costs for Q3 2023 were CNY 306,108,521.80, down 36.0% from CNY 478,638,335.45 year-on-year[24] Other Income and Expenses - Other income increased by 297.27% to ¥3,862,406.30, mainly due to higher government subsidies received[11] - Research and development expenses for Q3 2023 were CNY 25,170,788.68, down 11.5% from CNY 28,351,916.96 in the previous year[25] - The company reported a financial income of CNY 8,434,404.25, compared to CNY 9,744,166.59 in the same period last year, indicating a decrease of 13.5%[25] Tax and Employee Payments - The company reported a total payment of ¥101,234,864.65 to employees, which increased from ¥96,281,347.04 in the same quarter last year, a rise of about 5%[28] - The total tax payments made were ¥50,757,346.59, compared to ¥43,032,197.31 in Q3 2022, indicating an increase of approximately 17.5%[28] Audit Status - The company has not undergone an audit for the Q3 2023 report[29]

程》的规定，所包含的信息能够从各方面真实地反映公司报告期内的 经营管理和财务状况等事项； 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）第五届监事会 第十一次会议于 2023 年 10 月 23 日在北京市北京经济技术开发区兴 海路 5 号公司二层会议室以通讯方式召开。本次会议通知于 2023 年 10 月 17 日以邮件方式向全体监事发出，与会的各位监事已知悉与所 审议事项相关的必要信息。本次会议由公司监事会主席林冠宇先生主 持，应出席本次会议的监事 3 名，亲自出席监事 3 名。本次会议的召 集和召开符合《公司法》及《公司章程》等相关法律法规的规定。经 全体监事认真审议，表决通过以下议案： 一、审议通过《关于 2023 年第三季度报告的议案》 监事会对公司 2023 年第三季度报告进行了审核，提出如下审核 意见： 1、公司董事会编制和审核公司 2023 年第三季度报告的程序符合 法律、行政法规、中国证监会和深圳证券交易所的有关规定，报告内 容真实、准确、完整地反映了公司 2023 年第三季度经营的实际情况， ...

一、审议通过《关于 2023 年第三季度报告的议案》 董事会认为公司已严格按照相关法律、法规及中国证监会和深圳证 券交易所的规定，编制公司《2023 年第三季度报告》。报告内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 北京利德曼生化股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")第五届董事会第十 三次会议于 2023 年 10 月 23 日在北京市北京经济技术开发区兴海路 5 号公司二层会议室以通讯方式召开。本次会议通知于 2023 年 10 月 17 日以邮件方式送达全体董事，与会的各位董事已知悉与所审议事项相关 的必要信息。本次会议由董事长王凯翔先生主持，应出席本次会议的董 事 7 名，亲自出席会议的董事 7 名。公司监事和高级管理人员列席了本 次会议。本次会议的召集和召开符合《公司法》和《公司章程》等有关 规定，会议所形成的有关决议合法、有效。经全体董事认真审议，表决 通过以下议案： 证券代码：300289 证券简 ...

证券代码：300289 证券简称：利德曼 公告编号：2023-054 北京利德曼生化股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")于 2023 年 3 月 15 日召开第五届董事会第九次会议和第五届监事会第七次会议，审议通过 了《关于继续使用部分闲置自有资金进行委托理财的议案》，同意公司及 子公司使用额度不超过人民币 50,000 万元的暂时闲置自有资金进行委托 理财，用于购买银行、证券公司、信托公司、基金管理公司等金融机构 发行的安全性高、流动性好、中低风险的现金管理类产品或理财产品等， 上述额度自公司董事会审议通过之日起 12 个月内可循环滚动使用。具体 内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《关于继续使 用闲置自有资金进行委托理财的公告》（公告编号：2023-012）、《关于使 用闲置自有资金进行委托理财的进展公告》（公告编号：2023-040）。 近日，公司使用自有资金购买的理财产品已到期赎回，并继续使用 自有资金进行 ...

证券代码：300289 证券简称：利德曼 公告编号：2023-053 北京利德曼生化股份有限公司 关于公司涉及诉讼的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1．案件所处的诉讼阶段：二审判决； 2．公司所处的当事人地位：本诉原告；反诉被告； 3．涉案的金额：本诉为 56,129,397.53 元及相应利息；反诉为 47,21 4,531.07 元及相应利息。 4．对公司损益产生的影响：本次判决为终审判决，法院驳回上诉， 维持原判。公司 2022 年度已根据一审判决结果确认预计负债 3,259.62 万 元。结合一审和二审判决结果，远鸿医疗应向公司返还对应的货物（如 无法返还，则扣减相应货款），公司预计新增利息支出 77.18 万元（暂计 至 2023 年 9 月 28 日利息），将对本年度利润产生影响。 与远鸿医疗双方因不服一审判决，依法向北京市第二中级人民法院提起 上诉，具体内容详见公司于 2023 年 2 月 24 日披露的《关于公司涉及诉 讼的进展公告》（公告编号：2023-006）。 一、诉讼案件的进展情况 公司近日收到 ...

证券代码：300289 证券简称：利德曼 1 北京利德曼生化股份有限公司 投资者关系活动记录表 编号：2023-002 | --- | --- | --- | |------------------------|-------------------------------------|---------------------------------------------------------------------------| | 投资者关系活动类别 | □特定对象调研■业绩说明会 □□现场参观 | □分析师会议 □媒体采访 新闻发布会 □路演活动□其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 参与公司 2023 | 年半年度网上业绩说明会的投资者 | | 时间 | 2023 年 8 月 18 日 | 15:00-16:00 | | 地点 | "利德曼投资者关系"微信小程序 | | | | | 副总裁（代行总裁职责）丁耀良先生 | | 上市公司接待人员姓名 | 副总裁兼董事会秘书财务负责人 | 张丽华女士欧阳旭先生 | 北京利德曼生化股份有限公司 2023 年半年度业绩说 明会 ...

证券代码：300289 证券简称：利德曼 公告编号：2023-050 北京利德曼生化股份有限公司 关于举行2023年半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特此公告。 北京利德曼生化股份有限公司 北京利德曼生化股份有限公司（以下简称"公司"）已于 2023 年 8 月 12 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2023 年半年度报告》及《2023 年半年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于 2023 年 8 月 18 日（星期五）下午 15:00 至 16:00 时举行 2023 年半年 度业绩说明会。本次半年度业绩说明会将采取网络远程方式举行，投 资者可通过以下方式参与本次互动交流： 参与方式一：在微信中搜索"利德曼投资者关系小程序"； 参与方式二：微信扫描以下二维码： 投资者依据提示，授权登入"利德曼投资者关系"小程序，即可 参与交流。 为提升交流效率和针对性，以及做好中小投资者保护工作，广泛 听取投资者的意见和建议，增进投资者对公司的了解和认同，提升 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥226,953,339.05, a decrease of 39.36% compared to ¥374,278,326.17 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥16,488,022.38, down 31.12% from ¥23,935,722.03 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥13,526,480.11, a decline of 35.82% compared to ¥21,074,994.36 in the same period last year[19]. - The basic earnings per share decreased to ¥0.0303, down 31.14% from ¥0.0440 in the same period last year[19]. - The company achieved operating revenue of 226.95 million yuan, a decrease of 39.36% year-on-year, and a net profit attributable to shareholders of 16.49 million yuan, down 31.12% year-on-year[39]. - The net profit for the first half of 2023 was CNY 19,482,806.84, a decrease of 45.9% compared to CNY 35,931,602.78 in the same period of 2022[199]. - The operating profit for the first half of 2023 was CNY 24,274,616.60, down 46.0% from CNY 44,957,089.56 in the previous year[199]. - The total comprehensive income for the first half of 2023 was CNY 19,482,806.84, a decrease of 45.9% from CNY 35,931,602.78 in the previous year[200]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,936,870,025.87, a decrease of 3.02% from ¥1,997,134,641.92 at the end of the previous year[19]. - The company's total assets as of June 30, 2023, amounted to CNY 2,104,671,954.30, slightly up from CNY 2,102,669,961.22 at the beginning of the year[197]. - The company's current assets totaled CNY 1,080,916,720.28, down from CNY 1,110,505,444.50 at the beginning of the year, reflecting a decrease of approximately 2.5%[191]. - The total liabilities decreased to CNY 107,311,546.01 from CNY 173,885,049.05, a decline of 38.2%[197]. - The company's equity attributable to shareholders increased to CNY 1,997,360,408.29 from CNY 1,928,784,912.17, reflecting a growth of 3.4%[197]. Research and Development - The total R&D investment for the company in the reporting period was ¥16.48 million, a decrease of 1.69% year-on-year, representing 7.26% of the operating revenue[55]. - The company has invested in the development of 43 immunodiagnostic reagent projects, with 5 new projects added during the reporting period[54]. - The company is actively expanding into molecular diagnostics and POCT, with 3 projects in different stages of development for molecular diagnostic reagents[55]. - The company has established a research and development team of 77 people, accounting for 14.81% of the total workforce, with 33 holding master's degrees or higher[63]. - The company has developed proprietary technologies that enhance the sensitivity and stability of diagnostic products compared to similar products in the market[63]. Market and Product Development - The company is focusing on self-research and collaborative development to enhance product competitiveness, establishing a cross-departmental project management model[37]. - The company is actively expanding its overseas market presence, leveraging the growing influence of domestic in vitro diagnostic manufacturers abroad[40]. - The company is enhancing its marketing capabilities and product offerings, including the introduction of specialized testing projects and upgrades to its chemiluminescence detection systems[40]. - The company is in the product development stage for multiple immunoassay kits, including prostate-specific antigen (PAP) and various tumor markers, aiming to enhance cancer detection packages[56]. - The company is working on a series of immunoassay kits for inflammation and hormone detection, which will diversify its testing categories[56]. Environmental Compliance - The company is classified as a key pollutant discharge unit, adhering to strict environmental standards for wastewater and emissions management[112]. - Beijing Lidman invested CNY 18.17 million in environmental protection measures during the reporting period, including CNY 10.70 million for wastewater treatment and CNY 4 million for air pollution control[119]. - The company achieved a total wastewater discharge of 0.27 tons and a total annual discharge of 4.26 tons, with all pollutant emissions within the regulatory limits[114]. - The company has implemented an online monitoring system for wastewater, which has been operational since 2021 and is connected to the Beijing Ecological Environment Bureau[115]. - The company has maintained all pollutant emissions below the limits set by its discharge permits during the reporting period[116]. Governance and Compliance - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance structure[125]. - The company has established a comprehensive governance structure to protect shareholder rights and ensure compliance with relevant laws[125]. - The company guarantees that all related transactions with the listed company will be fair and conducted according to normal commercial practices, ensuring compliance with relevant regulations[136]. - The company has committed to ensuring that all related transactions are disclosed in accordance with legal and regulatory requirements, maintaining transparency with shareholders[136]. - The company has not engaged in any related party transactions during the reporting period[164]. Future Outlook - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 25% driven by new product launches and market expansion[139]. - The company plans to enhance its online sales platform, aiming for a 30% increase in e-commerce revenue by the end of 2023[140]. - The company has allocated 200 million RMB for research and development in innovative technologies over the next year[139]. - The company aims to enhance operational efficiency, targeting a reduction in operational costs by 15% by the end of 2023[139]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[139].

2、报告期内，公司不存在为控股股东及其他关联方、其他法人 单位或个人提供担保的情形。公司也不存在以前年度发生并累积至 2023 年 6 月 30 日的对外担保情形。 二、关于 2023 年半年度募集资金存放与实际使用情况专项报告 的独立意见 经核查，我们认为：公司 2023 年上半年对募集资金的存放和使 用管理严格按照有关法律、行政法规、规范性文件及公司相关制度的 要求，不存在募集资金存放和使用违规及变相改变募集资金用途的情 形，也不存在损害公司股东特别是中小投资者利益的情况。公司编制 的《2023 年半年度募集资金存放与实际使用情况的专项报告》内容 真实、准确、完整、不存在虚假记载、误导性陈述和重大遗漏。 独立董事：王艳、张志谦、安娜 北京利德曼生化股份有限公司独立董事 关于第五届董事会第十二次会议相关事项的独立意见 根据中国证券监督管理委员会《上市公司独立董事规则》、《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等相关法律法规及规范性文件以及《北京利德曼生化股份有限公 司独立董事制度》的有关规定，我们作为北京利德曼生化股份有限公 司（以下简称"公司"）的独立董事，本着对全体股 ...